 The FDA has signed off BioCardia Incs NASDAQ: BCDA Investigational New Drug IND application for BCDA-04 to initiate Phase 12 trial in adult patients recovering from Acute Respiratory Distress Syndrome ARDS due to COVID-19. BCDA-04 is a proprietary allogeneic mesenchymal. 